Demographics, baseline features and clinical outcomes of 95 patients infected with SARS-CoV-2
| All patients (n=95) | Patients with GI symptoms (n=58) | Patients without GI symptoms (n=37) | P value | |
| Age, years | 45.3±18.3 | 48.0±17.1 | 41.1±19.5 | 0.073 |
| Age groups | ||||
| <15 | 5 (5.3) | 1 (1.7) | 4 (10.8) | 0.30 |
| 15–39 | 37 (38.9) | 23 (39.7) | 14 (37.9) | |
| 40–49 | 9 (9.5) | 5 (8.6) | 4 (10.8) | |
| 50–64 | 31 (32.6) | 19 (32.8) | 12 (32.4) | |
| ≥65 | 13 (13.7) | 10 (17.2) | 3 (8.1) | |
| Sex | ||||
| Female | 50 (52.6) | 31 (53.4) | 19 (51.4) | 0.84 |
| Male | 45 (47.4) | 27 (46.6) | 18 (48.6) | |
| Epidemiological history | ||||
| Recently been to Wuhan or surrounding cities | 76 (80.0) | 45 (77.6) | 31 (83.8) | 0.46 |
| Contacted with people from Wuhan | 19 (20.0) | 13 (22.4) | 6 (16.2) | |
| Smoking history | ||||
| Current smoking | 6 (6.3) | 5 (8.6) | 1 (2.7) | 0.40 |
| Drinking history | ||||
| Current drinking | 9 (9.5) | 6 (10.3) | 3 (8.1) | 1.00 |
| Disease classification | ||||
| Non-severe | 75 (78.9) | 44 (75.9) | 31 (83.8) | 0.36 |
| Severe | 20 (21.1) | 14 (24.1) | 6 (16.2) | |
| Coexisting illness | ||||
| Hypertension | 16 (16.8) | 10 (17.2) | 6 (16.2) | 0.90 |
| Diabetes mellitus | 6 (6.3) | 3 (5.2) | 3 (8.1) | 0.67 |
| Cardio-cerebrovascular disease | 4 (4.2) | 3 (5.2) | 1 (2.7) | 1.00 |
| Malignant tumour | 5 (5.3) | 4 (6.9) | 1 (2.7) | 0.65 |
| Chronic lung disease | 5 (5.3) | 1 (1.7) | 4 (10.8) | 0.074 |
| Chronic kidney disease | 1 (1.1) | 1 (1.7) | 0 | 1.00 |
| Viral RNA detection | ||||
| Positive faeces | 31/65 (47.7) | 22/42 (52.4) | 9/23 (39.1) | 0.31 |
| Clinical outcome | ||||
| Remained in hospital | 58 (61.1) | 35 (60.3) | 23 (62.2) | 0.86 |
| Discharged | 37 (38.9) | 23 (39.7) | 14 (37.8) | |
| Died | 0 | 0 | 0 |
Data are presented as n (%), n/N (%) and N is the total number of patients with available data.
P value refers to the comparison between patients with GI symptoms and those without.
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.